Categorized | Melanoma In The News

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Source: Oncology Nurse Advisor, September 2017

Patients with advanced melanoma may experience significantly prolonged overall survival (OS) when treated with nivolumab plus ipilimumab compared with nivolumab or ipilimumab alone, according to a study published in The New England Journal of Medicine.

For the phase 3 Checkmate 067 study, researchers assigned patients with advanced melanoma 1:1:1 to receive nivolumab 3 mg/kg plus placebo, ipilimumab 3 mg/kg plus placebo, or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg followed by nivolumab 3 mg/kg. Patients were stratified according to programmed death ligand 1 (PDL-1) status, melanomaBRAF mutation status, and metastasis stage.

Median overall survival was not reached by patients in the nivolumab-plus-ipilimumab arm at the minimum follow-up of 36 months, and was 37.6 months among patients in the nivolumab group and 19.9 months among patients in the ipilimumab group (hazard ratio [HR] for death with nivolumab plus ipilimumab vs ipilimumab, 0.55 [P <.001]; HR for death with nivolumab vs ipilimumab, 0.65 [P <.001]).

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories